VJHemOnc Podcast

Deepti Radia, a hematological neoplasm expert, discusses the challenges of treating systemic mastocytosis and associated hematological neoplasms. She highlights promising targeted treatments and explores available options, including anti-mediated therapies. The podcast also covers the management of these patients during the COVID-19 pandemic.

Experts discuss the utilization of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) for treatment guidance and therapy efficacy comparison. They explore the challenges and potential of molecular and flow cytometry approaches, standardized MRD assessment, risk stratification, and the need for further research and methodology harmonization.

Prof. Mohamad Mohty discusses managing myeloma patients during the COVID-19 era, including protecting patients from infection, minimizing hospital visits, and alternative treatment options.

CAR-T cell therapy shows promise as a treatment for refractory CLL. It has short treatment duration, high rates of MRD negativity, and more tolerable toxicities. Combining Bruteinibt with CAR-T cell therapy yields high response rates and lower toxicity. Advancements in CLL treatment and the impact of risk factors on CAR T-cell response are discussed. CAR-T cell therapy for CLL patients with high-risk genetics shows deep and durable responses. Optimism grows for integrating CAR-T into CLL treatment landscape.

This podcast discusses the potential and impressive results of CAR-T cell therapy for multiple myeloma, including high response rates and manageable toxicities. It explores the use of different antigens and cells from different sources in CAR-T cell therapy, as well as strategies to enhance efficacy and potential future directions.

Discussion on targeting the lymphoma tumor microenvironment, including combining epigenetic therapies with immune therapies. Challenges and the need for combination therapies in lymphoma therapy. Impact of alterations in MHC class 1 and B2M in lymphoma and challenges in studying these changes.

Experts Patrick Thornton, Petra Langerbeins, and Alessandra Tedeschi discuss the latest trial updates and innovative therapies for CLL, including the efficacy of novel drugs, chemo-free treatments, non-covalent binders, and CD19 targeted autologous CAR T-cell therapy.

This podcast discusses the development of innovative therapies for relapsed and refractory lymphoma, focusing on epigenetic dysregulation and targeted therapies. It explores the role of the epigenome, key mutations affecting histone modifiers, and the potential for epigenetic therapies to restore immune function.

The podcast explores the evolution of induction therapy in myeloma treatment, including the impact of triplet regimens and the effectiveness of adding a monoclonal antibody. It also discusses advancements such as novel generation immunomodulatory drugs and optimizing transplant components.

Experts discuss advancements in acute leukemia therapy, including the use of measurable residual disease and CAR T-cell therapy. Challenges in immune therapies for acute myeloid leukemia are explored, along with the potential of small molecules and combination therapies. A study combining bortezumib and dixymethasone for acute leukemia therapy is examined, despite being halted due to increased toxicity. The difficulties of subgroup studies in acute myeloid leukemia are discussed, emphasizing the need for innovative approaches. A recent meeting on acute leukemia therapy is reflected upon, highlighting the importance of choosing relevant topics and positive interactions with pharmaceutical companies and colleagues.